(Q24241144)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

Saw palmetto for benign prostatic hyperplasia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

Serenoa repens for benign prostatic hyperplasia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

Complementary and alternative medicine use among adults: United States, 2002

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

27 September 2017

Plant extracts in BPH.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

Treatment of benign prostatic hyperplasia with phytosterols

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

Clinical manifestations of benign prostatic hyperplasia and indications for therapeutic intervention

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

Clinical trials in psychiatry: should protocol deviation censor patient data?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

Phytotherapy for the prostate

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

Symptomatic treatment of benign hypertrophy of the prostate. Comparative study of prazosin and serenoa repens

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

The Assessment of Prostatic Obstruction from Urodynamic Measurements and from Residual Urine

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial

30 May 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001423.PUB2

Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001423.PUB2

A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001423.PUB2

Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms--a placebo-controlled, double-blind, multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001423.PUB2

Randomized trial of a combination of natural products (cernitin, saw palmetto, B-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001423.PUB2

Long-term efficacy of Serenoa repens treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001423.PUB2

BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001423.PUB2

Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001423.PUB2

Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001423.PUB2

Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Chicago

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001423.PUB2

Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001423.PUB2

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001423.PUB2

Phytotherapy in treatment of benign prostatic hyperplasia: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001423.PUB2

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001423.PUB2

Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001423.PUB2

Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001423.PUB2

Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

[Efficacy of pretreatment with Serenoa repens on bleeding associated with transurethral resection of prostate].

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090655

[Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Aiken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study]

29 November 2018

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms

1 reference

12 December 2020

The development of human benign prostatic hyperplasia with age

1 reference

12 December 2020

[Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of Serenoa repens. Double-blind clinical study vs. placebo]

1 reference

12 December 2020

The value of permixon in benign prostatic hypertrophy

1 reference

12 December 2020

Conservative, non-hormonal treatment of benign prostatic hyperplasia

1 reference

12 December 2020

Variance imputation for overviews of clinical trials with continuous response

1 reference

12 December 2020

Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients

1 reference

12 December 2020

Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research

1 reference

12 December 2020

Growing use of medicinal botanicals forces assessment by drug regulators

1 reference

12 December 2020

Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia

1 reference

12 December 2020

Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia

1 reference

12 December 2020

Enzyme activities in tissue of human benign prostatic hyperplasia after three months' treatment with the Sabal serrulata extract IDS 89 (Strogen) or placebo

1 reference

12 December 2020

Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men

1 reference

12 December 2020

Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms

1 reference

12 December 2020

[Efficacy of a combined Sabal-urtica preparation in the symptomatic treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study]

1 reference

12 December 2020

[Combined extract of Sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in double blind, placebo-controlled trial]

1 reference

12 December 2020

Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China

1 reference

12 December 2020

Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial

1 reference

12 December 2020

[Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study]

1 reference

12 December 2020

Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract ofSerenoa repens (LSESr, Permixon�) in benign prostatic hyperplasia

1 reference

12 December 2020

The lipidosterolic extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a comparison of two dosage regimens.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001423.PUB2

7 January 2021

inferred from DOI database lookup

Early urodynamic effects of the lipido-sterolic extract of Serenoa repens (Permixon(R)) in patients with lower urinary tract symptoms due to benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001423.PUB2

7 January 2021

inferred from DOI database lookup

[Associating Serenoa repens, Urtica dioica and Pinus pinaster. Safety and efficacy in the treatment of lower urinary tract symptoms. Prospective study on 320 patients]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001423.PUB2

7 January 2021